353: Trump's drug-pricing plan and a potential Theranos 2.0
The Readout Loud
00:00
Intro
This chapter explores recent events in the biotech sector, focusing on Trump's drug pricing plan and the controversies surrounding Robert F. Kennedy Jr. The speakers also raise alarms about a new blood-testing company that may face scrutiny similar to Theranos, setting a critical tone for further analysis.
Transcript
Play full episode
